siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 4, 2008, Pages 503-513

  Niu, Jian ^a   Li, Xiang Nong ^a   Qian, Haixin ^b   Han, Zeguang ^c  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b SUZHOU UNIVERSITY   (China)

^c CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Combined anti cancer therapy; Insulin like growth factor type I receptor; siRNA; The epidermal growth factor receptor

Indexed keywords

CASPASE 3; CASPASE 8; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL GROWTH; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CANCER; NICK END LABELING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40049093852     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0314-x     Document Type: Article

References (57)

1. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB (1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282:615-616
2. Albanell J, Baselga J (1996) Unraveling resistance to trastuzuMAb (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93:1830-1832
3. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ (2001) ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFRpositive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94:774-782
4. Aplen NJ, Parrish S, Imani F, Fire A, Morgan RA (2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 98:9742-9747
5. Arteaga C (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7:31-39
6. Ass BL (2000) Double-stranded RNA as a template for gene silencing. Cell 101:235-238
7. Bailey LR, Janas M, Schmidt K, Bindslev N, Wolf M, Grous J, Askaa J, Herbst R, Johnson DH, Giacone G (2004) Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. J Clin Oncol 22:S7013
8. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822
9. Busse D, Doughty RS, Ramsey TT, Russel WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL (2000) Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275:6987-6995
10. Camirand A, Pollak M (2004) Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 90:1825-1829
11. Camirand A, Lu Y, Pollak M (2002) Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8:BR521-BR526
12. Camirand A, Zakikhani M, Young F, Pollak M (2005) Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7:570-579
13. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L, Fumagalli M, Menard S, Gianni L (2004) Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 198:259-268
14. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200-207
15. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063
16. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Raffaele Bianco A, Tortora G (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa)1, a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465
17. Connolly JM, Rose DP (1994) Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24:167-175
18. Coppola D, Ferber A, Miura M, Sell C, D'Ambrosio C, Rubin R, Baserga R (1994) A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 14:4588-4595
19. Dancey JE, Freidlin B (2003) Targeting epidermal growth factor receptor-are we missing the mark? Lancet 362:62-64
20. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 411:494-498
21. Freed KA, Herington AC (1989) Insulin-like growth factor-I and its auto-crine role in growth of MCF-7 human breast cancer cells in culture. J Mol Endocrinol 3:183-190
22. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro H-G, Cozens R, Evans DB, Fabbro D, Furet P, Graus-Porta D, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F (2004) In vivo anti-tumor activity of NVPAEW541-a novel, potent and selective inhibitor of the IGF1R kinase. Cancer Cell 5:231-239
23. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia NA (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316-328
24. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1(IGFR-1) in benign and malignant breast tissue. J Pathol 183:412-417
25. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215-244
26. Lee TC, Zhang Y, Aston C, Hintz R, Jagirdar J, Perle MA, Burt M, Rom WN (1993) Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 53:2858-2864
27. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001a) Insulin-like growth factor-I receptor signaling and resistance to trastuzuMAb (Herceptin). J Natl Cancer Inst 93:1852-1857
28. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001b) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857
29. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z (2004) Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with fully human recombinant bispecific antibodies. J Biol Chem 279:2856-2865 (Epub ahead of print)
30. Lynch TH, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl J Med 350:2129-2139
31. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou X-M, Blattler WA, Chittenden T, Singh R (2003) An anti-insulin-like growth factor-I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073-5083
32. Mendelsohn J, Baselga J (2000) The EGFR family as targets for cancer therapy. Oncogene 19:6550-6565
33. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA et al (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221-230
34. Moasser MM, Basso A, Averbuch SD, Rosen N (2001) The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188
35. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
36. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895
37. Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F (1988) Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 82:354-359
38. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65-72
39. Ozanne B, Richards CS, Hendler F (1986) Overexpression of the EGFR is a hallmark of squamous cell carcinomas. J Pathol 149:9-14
40. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
41. Pietrzkowski Z, Lammers R, Carpenter G, Soderquist AM, Limardo M, Phillips PD, Ullrich A, Baserga R (1992) Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ 3:199-205
42. Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224-1228
43. Pollak M, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518
44. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, Klocker H (1999) Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59:227-233
45. She QB, Solit D, Basso A, Moasser MM (2003) Resistance to Gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9:4340-4346
46. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892
47. Steinbach JP, Eisenmann C, Klumpp A, Weller M (2004a) Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun 321:524-530
48. Steinbach JP, Klumpp A, Wolburg H, Weller M (2004b) Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 64:1575-1578
49. Tezuka M, Watanabe H, Nakamura S, Yu D, Aung W, Sasaki T, Shibuya H, Miura M (2001) Antiapoptotic activity is dispensable for insulin-like growth factor I receptor-mediated clonogenic radioresistance after γ-irradiation. Clin Cancer Res 7:3206-3214
50. von Willebrand M, Zacksenhaus E, Cheng E, Glazer P, Halaban R (2003) The tyrphostin AG1024 accelerates the degradation of phosphorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cells. Cancer Res 63:1420-1429
51. Wang Y, Sun Y (2002) Insulin-like growth factor receptor-1 as an anticancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2:191-207
52. Warshamana-Grene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverria C, Krystal GW (2004) The insulin-like growth factor-I(IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signalling. Mol Cancer Ther 3:527-535
53. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-223
54. Wen B, Deutsch E, Marangoni E, Frascona V, Maggiorella L, Abdulkarim B, Chavaudra N, Bourhis J (2001) Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85:2017-2021
55. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J (1995) Apoptosis induced by an anti-EGFR monoclonal antibody in human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897-1905
56. Ye D, Mendelsohn J, Fan Z (1999) Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18:731-738
57. Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472-1489